Physician profile
Amanda E Potter
NPI 1730795246
$1,530.26
in general payments reported to CMS, 2019-2025
22 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.19 · 2022: $407 · 2023: $258 · 2024: $542 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.52 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $211.10 | 2022-2023 | Azstarys |
| Abbvie INC. | $179.75 | 2022-2025 | |
| Novo Nordisk INC | $172.85 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Organon LLC | $170.49 | 2024 | |
| Amgen INC. | $121.54 | 2022-2025 | Otezla, Repatha, Evenity |
| Genentech USA, INC. | $105.32 | 2021-2022 | |
| Astellas Pharma US INC | $91.89 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $45.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.13 | 2024-2025 | |
| Lilly USA, LLC | $42.75 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Shield Therapeutics INC | $41.71 | 2024-2025 | |
| Boston Scientific Corporation | $40.77 | 2024 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $38.76 | 2025 | Myfembree |
| Astrazeneca Pharmaceuticals LP | $38.75 | 2022-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $36.53 | 2024 | Gardasil 9, Gardasil, Vaxelis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $30.70 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $29.63 | 2025 | |
| Astellas Pharma Global Development | $26.70 | 2025 | Veozah |
| Exeltis, USA INC. | $17.42 | 2025 | Slynd |
| Exact Sciences Corporation | $16.40 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.42 | 2022 | |
| Pfizer INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.